Mangiferin inhibits lipopolysaccharide-induced epithelial-mesenchymal transition (EMT) and enhances the expression of tumor suppressor gene PER1 in non-small cell lung cancer cells.
Identifieur interne : 000117 ( Main/Exploration ); précédent : 000116; suivant : 000118Mangiferin inhibits lipopolysaccharide-induced epithelial-mesenchymal transition (EMT) and enhances the expression of tumor suppressor gene PER1 in non-small cell lung cancer cells.
Auteurs : Yen-Sung Lin [Taïwan] ; Kun-Ling Tsai [Taïwan] ; Jia-Ni Chen [Taïwan] ; Chen-Shiou Wu [Taïwan]Source :
- Environmental toxicology [ 1522-7278 ] ; 2020.
Descripteurs français
- KwdFr :
- Antigènes CD (génétique), Antinéoplasiques d'origine végétale (pharmacologie), Cadhérines (génétique), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (génétique), Cellules A549 (MeSH), Humains (MeSH), Lignée cellulaire tumorale (MeSH), Lipopolysaccharides (pharmacologie), Mouvement cellulaire (effets des médicaments et des substances chimiques), Mouvement cellulaire (génétique), Petit ARN interférent (génétique), Prolifération cellulaire (effets des médicaments et des substances chimiques), Prolifération cellulaire (génétique), Protéines circadiennes Period (génétique), Récepteurs CXCR4 (génétique), Régulation négative (MeSH), Transduction du signal (MeSH), Transition épithélio-mésenchymateuse (effets des médicaments et des substances chimiques), Transition épithélio-mésenchymateuse (génétique), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (génétique), Vimentine (métabolisme), Xanthones (pharmacologie).
- MESH :
- anatomopathologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- effets des médicaments et des substances chimiques : Mouvement cellulaire, Prolifération cellulaire, Transition épithélio-mésenchymateuse.
- génétique : Antigènes CD, Cadhérines, Carcinome pulmonaire non à petites cellules, Mouvement cellulaire, Petit ARN interférent, Prolifération cellulaire, Protéines circadiennes Period, Récepteurs CXCR4, Transition épithélio-mésenchymateuse, Tumeurs du poumon.
- métabolisme : Vimentine.
- pharmacologie : Antinéoplasiques d'origine végétale, Lipopolysaccharides, Xanthones.
- Cellules A549, Humains, Lignée cellulaire tumorale, Régulation négative, Transduction du signal.
English descriptors
- KwdEn :
- A549 Cells (MeSH), Antigens, CD (genetics), Antineoplastic Agents, Phytogenic (pharmacology), Cadherins (genetics), Carcinoma, Non-Small-Cell Lung (genetics), Carcinoma, Non-Small-Cell Lung (pathology), Cell Line, Tumor (MeSH), Cell Movement (drug effects), Cell Movement (genetics), Cell Proliferation (drug effects), Cell Proliferation (genetics), Down-Regulation (MeSH), Epithelial-Mesenchymal Transition (drug effects), Epithelial-Mesenchymal Transition (genetics), Humans (MeSH), Lipopolysaccharides (pharmacology), Lung Neoplasms (genetics), Lung Neoplasms (pathology), Period Circadian Proteins (genetics), RNA, Small Interfering (genetics), Receptors, CXCR4 (genetics), Signal Transduction (MeSH), Vimentin (metabolism), Xanthones (pharmacology).
- MESH :
- chemical , genetics : Antigens, CD, Cadherins, Period Circadian Proteins, RNA, Small Interfering, Receptors, CXCR4.
- chemical , metabolism : Vimentin.
- chemical , pharmacology : Antineoplastic Agents, Phytogenic, Lipopolysaccharides, Xanthones.
- drug effects : Cell Movement, Cell Proliferation, Epithelial-Mesenchymal Transition.
- genetics : Carcinoma, Non-Small-Cell Lung, Cell Movement, Cell Proliferation, Epithelial-Mesenchymal Transition, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- A549 Cells, Cell Line, Tumor, Down-Regulation, Humans, Signal Transduction.
Abstract
Non-small cell lung cancer (NSCLC) is often complicated by pulmonary infection, which affects treatment and prognosis. Bacterial lipopolysaccharide (LPS) is an effective stimulator of inflammatory cytokine production, and previous studies have reported that LPS promotes tumor invasion and metastasis. Mangiferin is a plant-derived C-glucosylxanthone with many biological activities, such as antioxidation and anti-inflammation. This research mainly explored the mechanism of its antitumor activities on LPS-induced A549, NCI-H460, and NCI-H520 NSCLC cells. We determined that mangiferin exhibits growth inhibiting activity against LPS-induced NSCLC cells through the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. In addition, mangiferin reversed the LPS-induced downregulation of E-cadherin (epithelial marker); conversely, it significantly inhibited the expression of raised vimentin (mesenchymal markers). Moreover, the ability of NSCLC cells to migrate, as evidenced by the wound healing and transwell migration assays, and the expression of CXCR4 increased by LPS were significantly repressed by mangiferin. In addition, mangiferin markedly mediated protein levels of PER1 and NLRP3 in LPS-induced NSCLC cells and reduced the secretion of IL-1β. These results indicate that mangiferin is not only a remarkable anti-inflammatory compound but also an antitumor agent; thus, it has the potential for being developed into anti-inflammatory and antitumor drugs in the future.
DOI: 10.1002/tox.22943
PubMed: 32420661
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mangiferin inhibits lipopolysaccharide-induced epithelial-mesenchymal transition (EMT) and enhances the expression of tumor suppressor gene PER1 in non-small cell lung cancer cells.</title><author><name sortKey="Lin, Yen Sung" sort="Lin, Yen Sung" uniqKey="Lin Y" first="Yen-Sung" last="Lin">Yen-Sung Lin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Pulmonary and Critical Care Medicine, An Nan Hospital, China Medical University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author><author><name sortKey="Tsai, Kun Ling" sort="Tsai, Kun Ling" uniqKey="Tsai K" first="Kun-Ling" last="Tsai">Kun-Ling Tsai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Jia Ni" sort="Chen, Jia Ni" uniqKey="Chen J" first="Jia-Ni" last="Chen">Jia-Ni Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Chen Shiou" sort="Wu, Chen Shiou" uniqKey="Wu C" first="Chen-Shiou" last="Wu">Chen-Shiou Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32420661</idno><idno type="pmid">32420661</idno><idno type="doi">10.1002/tox.22943</idno><idno type="wicri:Area/Main/Corpus">000128</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000128</idno><idno type="wicri:Area/Main/Curation">000128</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000128</idno><idno type="wicri:Area/Main/Exploration">000128</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mangiferin inhibits lipopolysaccharide-induced epithelial-mesenchymal transition (EMT) and enhances the expression of tumor suppressor gene PER1 in non-small cell lung cancer cells.</title><author><name sortKey="Lin, Yen Sung" sort="Lin, Yen Sung" uniqKey="Lin Y" first="Yen-Sung" last="Lin">Yen-Sung Lin</name><affiliation wicri:level="1"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Division of Pulmonary and Critical Care Medicine, An Nan Hospital, China Medical University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author><author><name sortKey="Tsai, Kun Ling" sort="Tsai, Kun Ling" uniqKey="Tsai K" first="Kun-Ling" last="Tsai">Kun-Ling Tsai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Jia Ni" sort="Chen, Jia Ni" uniqKey="Chen J" first="Jia-Ni" last="Chen">Jia-Ni Chen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Chen Shiou" sort="Wu, Chen Shiou" uniqKey="Wu C" first="Chen-Shiou" last="Wu">Chen-Shiou Wu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan</wicri:regionArea><wicri:noRegion>Tainan</wicri:noRegion></affiliation></author></analytic><series><title level="j">Environmental toxicology</title><idno type="eISSN">1522-7278</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A549 Cells (MeSH)</term><term>Antigens, CD (genetics)</term><term>Antineoplastic Agents, Phytogenic (pharmacology)</term><term>Cadherins (genetics)</term><term>Carcinoma, Non-Small-Cell Lung (genetics)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Cell Line, Tumor (MeSH)</term><term>Cell Movement (drug effects)</term><term>Cell Movement (genetics)</term><term>Cell Proliferation (drug effects)</term><term>Cell Proliferation (genetics)</term><term>Down-Regulation (MeSH)</term><term>Epithelial-Mesenchymal Transition (drug effects)</term><term>Epithelial-Mesenchymal Transition (genetics)</term><term>Humans (MeSH)</term><term>Lipopolysaccharides (pharmacology)</term><term>Lung Neoplasms (genetics)</term><term>Lung Neoplasms (pathology)</term><term>Period Circadian Proteins (genetics)</term><term>RNA, Small Interfering (genetics)</term><term>Receptors, CXCR4 (genetics)</term><term>Signal Transduction (MeSH)</term><term>Vimentin (metabolism)</term><term>Xanthones (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antigènes CD (génétique)</term><term>Antinéoplasiques d'origine végétale (pharmacologie)</term><term>Cadhérines (génétique)</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (génétique)</term><term>Cellules A549 (MeSH)</term><term>Humains (MeSH)</term><term>Lignée cellulaire tumorale (MeSH)</term><term>Lipopolysaccharides (pharmacologie)</term><term>Mouvement cellulaire (effets des médicaments et des substances chimiques)</term><term>Mouvement cellulaire (génétique)</term><term>Petit ARN interférent (génétique)</term><term>Prolifération cellulaire (effets des médicaments et des substances chimiques)</term><term>Prolifération cellulaire (génétique)</term><term>Protéines circadiennes Period (génétique)</term><term>Récepteurs CXCR4 (génétique)</term><term>Régulation négative (MeSH)</term><term>Transduction du signal (MeSH)</term><term>Transition épithélio-mésenchymateuse (effets des médicaments et des substances chimiques)</term><term>Transition épithélio-mésenchymateuse (génétique)</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (génétique)</term><term>Vimentine (métabolisme)</term><term>Xanthones (pharmacologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, CD</term><term>Cadherins</term><term>Period Circadian Proteins</term><term>RNA, Small Interfering</term><term>Receptors, CXCR4</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Vimentin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Lipopolysaccharides</term><term>Xanthones</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Movement</term><term>Cell Proliferation</term><term>Epithelial-Mesenchymal Transition</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Mouvement cellulaire</term><term>Prolifération cellulaire</term><term>Transition épithélio-mésenchymateuse</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Cell Movement</term><term>Cell Proliferation</term><term>Epithelial-Mesenchymal Transition</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes CD</term><term>Cadhérines</term><term>Carcinome pulmonaire non à petites cellules</term><term>Mouvement cellulaire</term><term>Petit ARN interférent</term><term>Prolifération cellulaire</term><term>Protéines circadiennes Period</term><term>Récepteurs CXCR4</term><term>Transition épithélio-mésenchymateuse</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Vimentine</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term><term>Lipopolysaccharides</term><term>Xanthones</term></keywords><keywords scheme="MESH" xml:lang="en"><term>A549 Cells</term><term>Cell Line, Tumor</term><term>Down-Regulation</term><term>Humans</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cellules A549</term><term>Humains</term><term>Lignée cellulaire tumorale</term><term>Régulation négative</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Non-small cell lung cancer (NSCLC) is often complicated by pulmonary infection, which affects treatment and prognosis. Bacterial lipopolysaccharide (LPS) is an effective stimulator of inflammatory cytokine production, and previous studies have reported that LPS promotes tumor invasion and metastasis. Mangiferin is a plant-derived C-glucosylxanthone with many biological activities, such as antioxidation and anti-inflammation. This research mainly explored the mechanism of its antitumor activities on LPS-induced A549, NCI-H460, and NCI-H520 NSCLC cells. We determined that mangiferin exhibits growth inhibiting activity against LPS-induced NSCLC cells through the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. In addition, mangiferin reversed the LPS-induced downregulation of E-cadherin (epithelial marker); conversely, it significantly inhibited the expression of raised vimentin (mesenchymal markers). Moreover, the ability of NSCLC cells to migrate, as evidenced by the wound healing and transwell migration assays, and the expression of CXCR4 increased by LPS were significantly repressed by mangiferin. In addition, mangiferin markedly mediated protein levels of PER1 and NLRP3 in LPS-induced NSCLC cells and reduced the secretion of IL-1β. These results indicate that mangiferin is not only a remarkable anti-inflammatory compound but also an antitumor agent; thus, it has the potential for being developed into anti-inflammatory and antitumor drugs in the future.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32420661</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-7278</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Environmental toxicology</Title><ISOAbbreviation>Environ Toxicol</ISOAbbreviation></Journal><ArticleTitle>Mangiferin inhibits lipopolysaccharide-induced epithelial-mesenchymal transition (EMT) and enhances the expression of tumor suppressor gene PER1 in non-small cell lung cancer cells.</ArticleTitle><Pagination><MedlinePgn>1070-1081</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/tox.22943</ELocationID><Abstract><AbstractText>Non-small cell lung cancer (NSCLC) is often complicated by pulmonary infection, which affects treatment and prognosis. Bacterial lipopolysaccharide (LPS) is an effective stimulator of inflammatory cytokine production, and previous studies have reported that LPS promotes tumor invasion and metastasis. Mangiferin is a plant-derived C-glucosylxanthone with many biological activities, such as antioxidation and anti-inflammation. This research mainly explored the mechanism of its antitumor activities on LPS-induced A549, NCI-H460, and NCI-H520 NSCLC cells. We determined that mangiferin exhibits growth inhibiting activity against LPS-induced NSCLC cells through the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. In addition, mangiferin reversed the LPS-induced downregulation of E-cadherin (epithelial marker); conversely, it significantly inhibited the expression of raised vimentin (mesenchymal markers). Moreover, the ability of NSCLC cells to migrate, as evidenced by the wound healing and transwell migration assays, and the expression of CXCR4 increased by LPS were significantly repressed by mangiferin. In addition, mangiferin markedly mediated protein levels of PER1 and NLRP3 in LPS-induced NSCLC cells and reduced the secretion of IL-1β. These results indicate that mangiferin is not only a remarkable anti-inflammatory compound but also an antitumor agent; thus, it has the potential for being developed into anti-inflammatory and antitumor drugs in the future.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yen-Sung</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Kun-Ling</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jia-Ni</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chen-Shiou</ForeName><Initials>CS</Initials><Identifier Source="ORCID">https://orcid.org/0000-0003-0791-1483</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences Industry, College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CJCU 108C120124</GrantID><Agency>Chang Jung Christian University, Tainan, Taiwan</Agency><Country></Country></Grant><Grant><GrantID>MOST 107-2320-B-309-001</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Environ Toxicol</MedlineTA><NlmUniqueID>100885357</NlmUniqueID><ISSNLinking>1520-4081</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C513384">CDH1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015820">Cadherins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C539022">PER1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056950">Period Circadian Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014746">Vimentin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044004">Xanthones</NameOfSubstance></Chemical><Chemical><RegistryNumber>1M84LD0UMD</RegistryNumber><NameOfSubstance UI="C013592">mangiferin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056950" MajorTopicYN="N">Period Circadian Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014746" MajorTopicYN="N">Vimentin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044004" MajorTopicYN="N">Xanthones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PER1</Keyword><Keyword MajorTopicYN="N">epithelial-mesenchymal transition</Keyword><Keyword MajorTopicYN="N">lipopolysaccharide</Keyword><Keyword MajorTopicYN="N">mangiferin</Keyword><Keyword MajorTopicYN="N">non-small cell lung cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32420661</ArticleId><ArticleId IdType="doi">10.1002/tox.22943</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.</Citation></Reference><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.</Citation></Reference><Reference><Citation>Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med. 2017;38(2):263-277.</Citation></Reference><Reference><Citation>Pchejetski D, Nunes J, Coughlan K, et al. The involvement of sphingosine kinase 1 in LPS-induced toll-like receptor 4-mediated accumulation of HIF-1alpha protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol. 2011;89(2):268-274.</Citation></Reference><Reference><Citation>Vlachostergios PJ, Gioulbasanis I, Ghosh S, et al. Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer. Clin Transl Oncol. 2013;15(11):903-909.</Citation></Reference><Reference><Citation>Melkamu T, Qian X, Upadhyaya P, O'Sullivan MG, Kassie F. Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer. Vet Pathol. 2013;50(5):895-902.</Citation></Reference><Reference><Citation>Liu WT, Jing YY, Yan F, et al. LPS-induced CXCR4-dependent migratory properties and a mesenchymal-like phenotype of colorectal cancer cells. Cell Adh Migr. 2017;11(1):13-23.</Citation></Reference><Reference><Citation>Hattar K, Savai R, Subtil FS, et al. Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer Immunol Immunother. 2013;62(2):309-320.</Citation></Reference><Reference><Citation>Yang N, Liang Y, Yang P, Ji F. Propofol suppresses LPS-induced nuclear accumulation of HIF-1alpha and tumor aggressiveness in non-small cell lung cancer. Oncol Rep. 2017;37(5):2611-2619.</Citation></Reference><Reference><Citation>Jiang M, Zhou LY, Xu N, An Q. Hydroxysafflor yellow a inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways. Thorac Cancer. 2019;10(6):1319-1333.</Citation></Reference><Reference><Citation>Chen MC, Chang WW, Kuan YD, Lin ST, Hsu HC, Lee CH. Resveratrol inhibits LPS-induced epithelial-mesenchymal transition in mouse melanoma model. Innate Immun. 2012;18(5):685-693.</Citation></Reference><Reference><Citation>Song J, Feng L, Zhong R, et al. Icariside II inhibits the EMT of NSCLC cells in inflammatory microenvironment via down-regulation of Akt/NF-kappaB signaling pathway. Mol Carcinog. 2017;56(1):36-48.</Citation></Reference><Reference><Citation>Kiessling S, Beaulieu-Laroche L, Blum ID, et al. Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC Biol. 2017;15(1):13-31.</Citation></Reference><Reference><Citation>Greene MW. Circadian rhythms and tumor growth. Cancer Lett. 2012;318(2):115-123.</Citation></Reference><Reference><Citation>Kettner NM, Katchy CA, Fu L. Circadian gene variants in cancer. Ann Med. 2014;46(4):208-220.</Citation></Reference><Reference><Citation>Fu XJ, Li HX, Yang K, Chen D, Tang H. The important tumor suppressor role of PER1 in regulating the cyclin-CDK-CKI network in SCC15 human oral squamous cell carcinoma cells. Onco Targets Ther. 2016;9:2237-2245.</Citation></Reference><Reference><Citation>Li HX, Fu XJ, Yang K, Chen D, Tang H, Zhao Q. The clock gene PER1 suppresses expression of tumor-related genes in human oral squamous cell carcinoma. Oncotarget. 2016;7(15):20574-20583.</Citation></Reference><Reference><Citation>Zhao H, Zeng ZL, Yang J, et al. Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer. Int J Clin Exp Pathol. 2014;7(2):619-630.</Citation></Reference><Reference><Citation>Zhao Q, Zheng G, Yang K, et al. The clock gene PER1 plays an important role in regulating the clock gene network in human oral squamous cell carcinoma cells. Oncotarget. 2016;7(43):70290-70302.</Citation></Reference><Reference><Citation>Liu B, Xu K, Jiang Y, Li X. Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer. Int J Clin Exp Pathol. 2014;7(11):7863-7871.</Citation></Reference><Reference><Citation>Bulugonda RK, Kumar KA, Gangappa D, et al. Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of NLRP3 inflammasome. Sci Rep. 2017;7:42683-42697.</Citation></Reference><Reference><Citation>Du S, Liu H, Lei T, et al. Mangiferin: An effective therapeutic agent against several disorders (review). Mol Med Rep. 2018;18(6):4775-4786.</Citation></Reference><Reference><Citation>Rivera DG, Hernandez I, Merino N, et al. Mangifera indica L. extract (Vimang) and mangiferin reduce the airway inflammation and Th2 cytokines in murine model of allergic asthma. J Pharm Pharmacol. 2011;63(10):1336-1345.</Citation></Reference><Reference><Citation>Li H, Huang J, Yang B, et al. Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and beta-catenin signaling pathway. Toxicol Appl Pharmacol. 2013;272(1):180-190.</Citation></Reference><Reference><Citation>Li M, Ma H, Yang L, Li P. Mangiferin inhibition of proliferation and induction of apoptosis in human prostate cancer cells is correlated with downregulation of B-cell lymphoma-2 and upregulation of microRNA-182. Oncol Lett. 2016;11(1):817-822.</Citation></Reference><Reference><Citation>Zhao J, Zhang B, Li S, Zeng L, Chen Y, Fang J. Mangiferin increases Nrf2 protein stability by inhibiting its ubiquitination and degradation in human HL60 myeloid leukemia cells. Int J Mol Med. 2014;33(5):1348-1354.</Citation></Reference><Reference><Citation>Mery B, Guy JB, Vallard A, et al. In vitro cell death determination for drug discovery: a landscape review of real issues. Journal of Cell Death. 2017;10:1-18.</Citation></Reference><Reference><Citation>Lee E, Han AR, Nam B, et al. Moscatilin induces apoptosis in human head and neck squamous cell carcinoma cells via JNK signaling pathway. Molecules. 2020;25(4):901-913.</Citation></Reference><Reference><Citation>Yu L, Chen M, Zhang R, Jin Z. Inhibition of cancer cell growth in gemcitabine-resistant pancreatic carcinoma by mangiferin phytochemical involves induction of autophagy, endogenous ROS production, cell cycle disruption, mitochondrial mediated apoptosis and suppression of cancer cell migration and invasion. J BUON. 2019;24(4):1581-1586.</Citation></Reference><Reference><Citation>Hou J, Zheng D, Xiao W, Li D, Ma J, Hu Y. Mangiferin enhanced autophagy via inhibiting mTORC1 pathway to prevent high glucose-induced cardiomyocyte injury. Front Pharmacol. 2018;9(383):1-9.</Citation></Reference><Reference><Citation>Chae YK, Chang S, Ko T, et al. Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci Rep. 2018;8(1):2918-2926.</Citation></Reference><Reference><Citation>Saba NF, Wang Y, Fu H, et al. Association of Cytoplasmic CXCR4 with loss of epithelial marker and activation of ERK1/2 and AKT signaling pathways in non-small-cell lung cancer. Clin Lung Cancer. 2017;18(3):e203-e210.</Citation></Reference><Reference><Citation>Jiang L, Fei D, Gong R, et al. CORM-2 inhibits TXNIP/NLRP3 inflammasome pathway in LPS-induced acute lung injury. Inflamm Res. 2016;65(11):905-915.</Citation></Reference><Reference><Citation>Zhang A, Pan W, Lv J, Wu H. Protective effect of amygdalin on LPS-induced acute lung injury by inhibiting NF-kappaB and NLRP3 signaling pathways. Inflammation. 2017;40(3):745-751.</Citation></Reference><Reference><Citation>Qin X, Jiang X, Jiang X, et al. Micheliolide inhibits LPS-induced inflammatory response and protects mice from LPS challenge. Sci Rep. 2016;6:23240-23253.</Citation></Reference><Reference><Citation>Sivandzade F, Bhalerao A, Cucullo L. Analysis of the mitochondrial membrane potential using the cationic JC-1 dye as a sensitive fluorescent probe. Bio-Protocol. 2019;9(1):e3128-e3141.</Citation></Reference><Reference><Citation>An J, Li Z, Dong Y, Ren J, Guo K. Methicillin-resistant Staphylococcus aureus infection exacerbates NSCLC cell metastasis by up-regulating TLR4/MyD88 pathway. Cell Mol Biol. 2016;62(8):1-7.</Citation></Reference><Reference><Citation>Grimm EA, Sikora AG, Ekmekcioglu S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res. 2013;19(20):5557-5563.</Citation></Reference><Reference><Citation>Li J, Lan T, Zhang C, et al. Reciprocal activation between IL-6/STAT3 and NOX4/Akt signalings promotes proliferation and survival of non-small cell lung cancer cells. Oncotarget. 2015;6(2):1031-1048.</Citation></Reference><Reference><Citation>Li Y, Li H, Liu S, et al. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Mol Immunol. 2018;99:134-144.</Citation></Reference><Reference><Citation>Li J, Yin J, Shen W, et al. TLR4 promotes breast cancer metastasis via Akt/GSK3beta/beta-catenin pathway upon LPS stimulation. Anat Rec. 2017;300(7):1219-1229.</Citation></Reference><Reference><Citation>Hsu RY, Chan CH, Spicer JD, et al. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res. 2011;71(5):1989-1998.</Citation></Reference><Reference><Citation>Xue Y, Xu W, Zhao W, Wang W, Zhang D, Wu P. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. Biomed pharmacother. 2017;86:426-433.</Citation></Reference><Reference><Citation>Zhu WB, Zhao ZF, Zhou X. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1alpha/CXCR4 signaling pathway in prostate cancer. J Cell Physiol. 2019;234(7):11746-11759.</Citation></Reference><Reference><Citation>Duang XY, Wang Q, Zhou XD, Huang DM. Mangiferin: a possible strategy for periodontal disease to therapy. Med Hypotheses. 2011;76(4):486-488.</Citation></Reference><Reference><Citation>Chen R, Yang K, Zhao NB, et al. Abnormal expression of PER1 circadian-clock gene in oral squamous cell carcinoma. Onco Targets Ther. 2012;5:403-407.</Citation></Reference><Reference><Citation>Zhao N, Yang K, Yang G, et al. Aberrant expression of clock gene period1 and its correlations with the growth, proliferation and metastasis of buccal squamous cell carcinoma. PLoS One. 2013;8(2):e55894-e558903.</Citation></Reference><Reference><Citation>Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res. 2017;5(2):94-99.</Citation></Reference><Reference><Citation>Qu S, Wang W, Li D, et al. Mangiferin inhibits mastitis induced by LPS via suppressing NF-kB and NLRP3 signaling pathways. Int Immunopharmacol. 2017;43:85-90.</Citation></Reference><Reference><Citation>Pan CW, Pan ZZ, Hu JJ, et al. Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Eur J Pharmacol. 2016;770:85-91.</Citation></Reference><Reference><Citation>Song J, Li J, Hou F, Wang X, Liu B. Mangiferin inhibits endoplasmic reticulum stress-associated thioredoxin-interacting protein/NLRP3 inflammasome activation with regulation of AMPK in endothelial cells. Metab Clin Exp. 2015;64(3):428-437.</Citation></Reference><Reference><Citation>Cao C, Su M, Zhou F. Mangiferin inhibits hippocampal NLRP3 inflammasome and exerts antidepressant effects in a chronic mild stress mice model. Behav Pharmacol. 2017;28(5):356-364.</Citation></Reference><Reference><Citation>Sumegi K, Fekete K, Antus C, et al. BGP-15 protects against oxidative stress- or lipopolysaccharide-induced mitochondrial destabilization and reduces mitochondrial production of reactive oxygen species. PLoS One. 2017;12(1):e0169372-e0169391.</Citation></Reference><Reference><Citation>Joseph LC, Kokkinaki D, Valenti MC, et al. Inhibition of NADPH oxidase 2 (NOX2) prevents sepsis-induced cardiomyopathy by improving calcium handling and mitochondrial function. JCI Insight. 2017;2(17):e94248-e94264.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Taïwan</li></country></list><tree><country name="Taïwan"><noRegion><name sortKey="Lin, Yen Sung" sort="Lin, Yen Sung" uniqKey="Lin Y" first="Yen-Sung" last="Lin">Yen-Sung Lin</name></noRegion><name sortKey="Chen, Jia Ni" sort="Chen, Jia Ni" uniqKey="Chen J" first="Jia-Ni" last="Chen">Jia-Ni Chen</name><name sortKey="Tsai, Kun Ling" sort="Tsai, Kun Ling" uniqKey="Tsai K" first="Kun-Ling" last="Tsai">Kun-Ling Tsai</name><name sortKey="Wu, Chen Shiou" sort="Wu, Chen Shiou" uniqKey="Wu C" first="Chen-Shiou" last="Wu">Chen-Shiou Wu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000117 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000117 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32420661
|texte= Mangiferin inhibits lipopolysaccharide-induced epithelial-mesenchymal transition (EMT) and enhances the expression of tumor suppressor gene PER1 in non-small cell lung cancer cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32420661" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |